Navigation Links
Mylan Applauds Obama Administration's Call to Create an "AIDS-Free Generation" Through Global Fight Against HIV/AIDS
Date:11/9/2011

PITTSBURGH, Nov. 9, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today applauded the Obama administration's call to action in the global fight against HIV/AIDS.

Mylan President Heather Bresch commented: "While the generics industry has made significant contributions toward making HIV/AIDS medicines more affordable, we believe the focus must now turn to expanding access to treatment for more people. As such, we're heartened that the Obama administration is embracing treatment as prevention and rallying global leaders to help end the global HIV/AIDS pandemic by making the creation of an 'AIDS-free generation' a policy priority. Achieving these objectives, as well as the goal of universal access set forth by the United Nations, will require close cooperation between governments, non-governmental organizations and the private sector."

Yesterday's speech by Secretary of State Hillary Clinton at the National Institutes of Health (NIH) comes at a critical time. Despite significant success in lowering infection rates, HIV/AIDS remains a leading cause of death globally and there are 7,000(1) new infections every day. Less than half of the estimated 15 million(2) people needing treatment receive it.

Recent scientific studies, including those conducted by NIH and the National Institute of Allergy and Infectious Diseases (NIAID), underscore the importance of early treatment. Evidence from these studies suggests that earlier initiation of treatment following testing and diagnosis may be the most effective means to prevent HIV transmission.

"With the 2012 International AIDS Society Conference taking place here in the U.S. in July 2012, the Obama administration has an ideal platform to take further steps to deliver on its commitments to addressing the global AIDS pandemic and make an 'AIDS-free generation' a reality. Mylan intends to do all it can to help by partnering with the administration, the U.N. and others to continue to expand access to high quality, affordable antiretrovirals used in the treatment of HIV/AIDS," concluded Bresch.

Approximately one-third of people in the developing world being treated for HIV/AIDS depend on a Mylan antiretroviral (ARV) product.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

(1) United Nations Program on HIV/AIDS
(2) World Health Organization


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan to Acquire Pfizer Respiratory Delivery Platform
2. Mylan Receives Approval for Generic Version of MS Contin® Tablets
3. Mylan Launches First Generic Version of Exelon® Capsules in the U.K.
4. Mylans Dey Pharma Successfully Obtains Patent Reexamination Certificates for Two Perforomist® Patents
5. Matrix Laboratories Completes Name Change to Mylan Laboratories
6. Mylan Announces Femcon® Fe Settlement Agreement
7. Mylan Announces Intention to Refinance Existing Secured Credit Facility
8. Mylan Comments on Death of Company Co-Founder and Former Chairman and CEO Milan "Mike" Puskar
9. Mylan Applauds Study Highlighting $931 Billion in Savings for U.S. Health Care System Due to Generic Drugs
10. Mylan Announces XELODA® Settlement and License Agreement
11. Mylans Matrix Receives Tentative FDA Approval Through PEPFAR for Novel "Co-Packaged" Version of HIV/AIDS Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Calif. , Feb. 4, 2016  Edwards Lifesciences ... patient-focused innovations for structural heart disease and critical care ... accelerated share repurchase (ASR) agreement with Morgan Stanley & ... stock.  This repurchase is part of the Company,s previously ... the Company,s common stock.  --> ...
(Date:2/4/2016)... , Feb. 4, 2016 Wegener ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline ... Wegener Polyangiitis,s therapeutic pipeline. This report provides ... Polyangiitis, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
(Date:2/4/2016)... 2016  Omnicell, Inc. (NASDAQ: OMCL ), a leading ... systems, today announced results for its fiscal year and ... --> GAAP results: Revenue for the ... million or 4.1% from the third quarter of 2015, ... quarter of 2014. Revenue for the year ended December 31, ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman ... Van Allen have signed a joint enrollment and degree completion agreement. The ... associate and baccalaureate degrees at FHU|Dickson. , The agreement allows students to ...
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps , ... Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally situated ... hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We ...
(Date:2/5/2016)... ... 05, 2016 , ... Regular gym users know the routine: each January, they ... access the treadmills. It’s a predictable trend. After the excesses of November and December, ... shape by joining gyms, starting new walking or running routines, or signing up for ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... in the 2015 Best in KLAS: Software & Services for HIT Implementation Support ... in KLAS report independently ranks vendor performance by healthcare executives, managers and clinicians ...
(Date:2/5/2016)... WORCESTER, MA (PRWEB) , ... February 05, 2016 , ... ... latest in tattoo technology, the PicoSure. Designed to provide the most effective tattoo removal ... cutting-edge option with unmatched results. , Developed by Cynosure, the PicoSure has been approved ...
Breaking Medicine News(10 mins):